NCT06372483View on ClinicalTrials.gov

Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 21, 2024

Primary Completion Date

August 7, 2024

Study Completion Date

August 31, 2026

Conditions
Coagulation Disorder
Interventions
DRUG

VMX-C001

VMX-C001 is human factor X engineered to be insensitive to factor Xa DOACs

DRUG

Placebo

VMX-C001 matched placebo

DRUG

Rivaroxaban 20 mg Oral Tablet

Fxa DOAC

DRUG

Apixaban 5 mg Oral Tablet

Fxa DOAC

DRUG

Edoxaban 60 mg Oral Tablet

Fxa DOAC

Trial Locations (1)

9728 NZ

ICON, Groningen

All Listed Sponsors
lead

VarmX B.V.

INDUSTRY

NCT06372483 - Single Dose Trial of VMX-C001 in Healthy Subjects with and Without FXa Direct Oral Anticoagulant | Biotech Hunter | Biotech Hunter